Clinical Drug Investigation

, Volume 27, Issue 11, pp 755–764 | Cite as

Economic Evaluation of Third-Line Treatment with Alemtuzumab for Chronic Lymphocytic Leukaemia

  • W. Guy Scott
  • Helen M. Scott
Original Research Article



The objective of this study was to compare the potential economic efficiency of third-line treatment of chronic lymphocytic leukaemia (CLL) with alemtuzumab versus fludarabine, cyclophosphamide and rituximab (FCR).


The target population for this study were patients with CLL who were able to tolerate third-line treatment with either FCR or alemtuzumab. The perspective used was that of the New Zealand Pharmaceutical Management Agency (PHARMAC)/District Health Board. Health outcomes considered were survival time from commencement of treatment and quality-adjusted life-years (QALYs) gained. Average costs and outcomes and incremental cost per patient treated, per survival month and per QALY gained, were calculated. All costs were presented in 2006 New Zealand dollars.


Base-case direct medical costs for alemtuzumab per treatment regimen per patient were $NZ15 303 lower than those for FCR. The average direct medical cost per survival month gained for alemtuzumab was $NZ3144 and for FCR was $NZ4101, and the average direct medical cost per QALY gained was $NZ46 016 and for FCR was $NZ60 012.


Third-line treatment of eligible patients with alemtuzumab was found to be $NZ15 303 less costly than FCR per patient.


Chronic Lymphocytic Leukaemia Fludarabine Alemtuzumab Direct Medical Cost Chronic Lymphocytic Leukaemia Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



A research grant from Bayer Schering Pharma, a division of Bayer New Zealand Limited, made this study possible but had no influence on the structure or content of the study research. Both authors were involved in all stages of the research and publishing process. At the time of the study the authors had no conflicts of interest that were directly relevant to the content of this study. One of the authors is now assisting with a PHARMAC application but was not doing so at the time of the study or writing of the paper.


  1. 1.
    Oscier D, Fegan C, Hillmen P, et al. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol 2004 May; 125: 294–317PubMedCrossRefGoogle Scholar
  2. 2.
    Gale RP, Cozen W, Goodman MT, et al. Decreased chronic lymphocytic leukemia incidence in Asians in Los Angeles County. Leuk Res 2000 Aug; 24(8): 665–9PubMedCrossRefGoogle Scholar
  3. 3.
    New Zealand Health Information Service. Cancer registrations and deaths 2002. New Zealand Ministry of Health, 2002Google Scholar
  4. 4.
    Data on file, latest registration figures for lymphocytic leukaemia. Wellington: New Zealand Health information Service, 2007Google Scholar
  5. 5.
    Everybody: health information for New Zealanders. Leukemia [online]. Available from URL: [Accessed 2007 Aug 13]
  6. 6.
    Keating MJ, Chiorazzi N, Messmer B, et al. Biology and treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2003: 153-75Google Scholar
  7. 7.
    Algorithm for patients with CLL requiring treatment. Auckland: Auckland District Health Board, 2007: 1Google Scholar
  8. 8.
    Robak T. Alemtuzumab in the treatment of chronic lymphocytic leukemia. BioDrugs 2005; 19(1): 9–22PubMedCrossRefGoogle Scholar
  9. 9.
    Keating M, Coutre S, Rai K, et al. Management guidelines for use of alenituzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 2004 Mar; 4(4): 220–7PubMedCrossRefGoogle Scholar
  10. 10.
    Drummond MF, O’Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. New York and Toronto: Oxford University Press, 1997Google Scholar
  11. 11.
    Thompson S, van Nooten F, van Agthoven M, et al. Cost and cost-effectiveness of FluCam versus FCR in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). 11th Congress of the European Haematology Association; 16–18 June 2006, AmsterdamGoogle Scholar
  12. 12.
    Thompson S, van Nooten F, van Agthoven M, et al. Cost- effectiveness of alemtuzumab (MabCampath®) in patients with B-cell chronic lymphocytic leukemia (CLL) who have failed alkylating agents and fludarabine. 11th Congress of the European Haematology Association; 16–18 June 2006, AmsterdamGoogle Scholar
  13. 13.
    Wierda W, O’Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005 Jun 20; 23(18): 4070–8PubMedCrossRefGoogle Scholar
  14. 14.
    New Zealand pharmaceutical schedule. Wellington, New Zealand: PHARMAC (Pharmaceutical Management Agency), 2006 AugGoogle Scholar
  15. 15.
    Data on file, New Zealand Health Information Service. Inpatient national prices. Wellington: New Zealand Health Information Service, 2006Google Scholar
  16. 16.
    New Zealand Ministry of Health. Hospital throughput 2002/03 [online]. Available from URL: [Accessed 2007 Aug 13]
  17. 17.
    Southern Cross Medical Care Society. VIP Plan 4 Schedule of benefits [online]. Available from URL: [Accessed 2007 Aug 13]
  18. 18.
    Data on file, prices of saline, giving set, syringes, IV venflon. Christchurch, New Zealand: Ebos, 2006Google Scholar
  19. 19.
    Laboratory test purchase list. Wellington, New Zealand: Central Regional Health Authority, 1997Google Scholar
  20. 20.
    Commerce Commission. Commerce Act 1986: Business Acquisition Section 66. Notice Seeking Clearance: New Zealand Diagnostic Group Ltd & Sonic Healthcare (New Zealand) Ltd [online]. Available from: [Accessed 2007 Aug 13]
  21. 21.
    Fraser G, Smith CA, Imrie K, et al. Alemtuzumab in chronic lymphocytic leukemia: a clinical practice guideline. Cancer Care Ontario; 2006 June 14. Report no.: 6-16: Section 1Google Scholar
  22. 22.
    Wierda W, O’Brien S, Faderl S, et al. A retrospective comparison of three sequential groups of patients with recurrent/ refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 2006; 106(2): 337–45PubMedCrossRefGoogle Scholar
  23. 23.
    Reserve Bank of New Zealand. Exchange rates and foreign exchange turnover, selected exchange rates and foreign exchange turnover data for selected currencies, B1 Exchange rates: bilateral rates and TWI [online]. Available from URL: [Accessed 2007 Aug 13]
  24. 24.
    Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002 May 15; 99(10): 3554–61PubMedCrossRefGoogle Scholar
  25. 25.
    Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002 Sep 15; 20(18): 3891–7PubMedCrossRefGoogle Scholar
  26. 26.
    Keating MJ, O’Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002; 43(9): 55–62CrossRefGoogle Scholar
  27. 27.
    Zikmund WG. Business research methods. Fort West: Harcourt Brace College Publishers, 2000Google Scholar
  28. 28.
    Devlin N, Hanson P, Kind P. The health state preferences and logical inconsistencies of New Zealanders: a tail of two tariffs. Heslington: University of York Centre for Health Economics, University of York. Working papers, 2000: 180Google Scholar
  29. 29.
    Grunberg SM, Srivastava A, Grunberg KJ, et al. Intensity of chemotherapy-induced emesis and overall survival as determinants of a global utility score. Support Care Cancer 2002 Nov; 10(8): 624–9PubMedCrossRefGoogle Scholar
  30. 30.
    Norum J, Angelsen V, Wist E, et al. Treatment costs in Hodgkin’s disease: a cost-utility analysis. Eur J Cancer 1996 Aug; 32A(9): 1510–7PubMedCrossRefGoogle Scholar
  31. 31.
    Wang XQ, Lin GW. Study on the quality of life in long-term survivors with acute leukemia in Shanghai [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi 2003 Nov; 24(11): 1049–51PubMedGoogle Scholar
  32. 32.
    @Risk version 4.5. Risk analysis and simulation add-in for Microsoft Excel. Newfield (NY): Palisade Corporation, 2004Google Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.ScottEconomicsWellingtonNew Zealand
  2. 2.Massey University at WellingtonWellingtonNew Zealand

Personalised recommendations